Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine (Q28372760)

0 references

T Iacovazzi

0 references

A Miglietta

0 references

A Guastadisegni

0 references

G Pastore

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

0 references

language of work or name

English

0 references

publication date

February 2000

0 references

published in

Journal of Hepatology

0 references

volume

0 references

issue

0 references

page(s)

300-6

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Precore mutant hepatitis B virus infection and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Lamivudine treatment for acute hepatitis B after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Clinical impact of lamivudine resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980076-8

7 January 2021

10.1016/S0168-8278(00)80076-8

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

10707871

1 reference

Consolidated OpenCitations Corpus – April 2017